在转移性黑色素瘤中使用或不使用免疫治疗的放射治疗:疗效和耐受性
Ellen Backlund1,2, Vitali Grozman3,4, Suzanne Egyhazi Brage2
1Department of Oncology, Karolinska University Hospital, Stockholm, Sweden.
Acta oncologica (Stockholm, Sweden)
|November 15, 2023
概括
将放射治疗 (RT) 与免疫检查点抑制剂 (ICI) 结合起来,可显著改善转移性黑色素瘤患者的抗瘤反应. 这种组合治疗,即使在疾病进展时开始,与单独RT相比,也显示出更高的疗效,从而导致更好的生存结果.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 辐射瘤学 辐射瘤学
背景情况:
- 放射治疗 (RT) 通常用于缓解转移性黑色素瘤.
- 免疫检查点抑制剂 (ICI) 可以增强抗瘤免疫反应.
- RT和ICI的组合可能会诱导腹膜效应,影响远程转移.
研究的目的:
- 评估RT与ICI在转移性黑色素瘤中结合的疗效.
- 为了比较在治疗开始时启动的RT加ICI的结果与在治疗进展时的结果.
- 评估组合疗法对abscopal效应和生存益处的评估.
主要方法:
- 在斯德哥尔摩 (2015-2020年) 接受非立体治疗的转移性黑色素瘤患者的回顾性研究.
- 患者被分为:RT + ICI (起始),RT + ICI (救援) 和RT (仅限).
- 评估的反应率 (照射和非照射),生存率和毒性.
主要成果:
- 组合疗法 (RT + ICI) 在照射病变 (70.7%和67.5%) 和单独RT (43.1%) 中显示出更高的响应率.
- 与RT单独 (0.0%) 相比,RT+ICI组的非辐射病变的整体应答率显著更高 (36.1%和14.8%).
- 组合治疗 (18.2个月和15.0个月) 与单独RT治疗 (7.2个月) 的平均整体存活时间明显较长.
结论:
- 接受RT结合ICI的转移性黑色素瘤患者表现出优异的抗瘤反应和生存率.
- 即使在进展 (救援) 时启动RT加ICI,也会产生显著的益处,包括腹膜效应.
- 在所有治疗组中,RT的局部反应与改善的生存率相关.
相关概念视频
Tumor Immunotherapy
533
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
533
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K


